Keratin, fas, and cryptogenic liver failure

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

Volumn 8, Issue 12, 2002, Pages 1195-1197

  Sorom, Abraham J ^a   Nyberg, Scott L ^a   Gores, Gregory J ^b  

^a Division of Transplantation   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 8; FAS ANTIGEN; KERATIN; KRT8 PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC HEPATITIS; GENETICS; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; MISSENSE MUTATION;

AMINO ACID SUBSTITUTION; ANTIGENS, CD95; BIOLOGICAL MARKERS; HEPATITIS, CHRONIC; HUMANS; KERATIN-8; KERATINS; LIVER FAILURE; LIVER TRANSPLANTATION; MUTATION, MISSENSE;

EID: 1842848005     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.0081195     Document Type: Article

References (16)

1. 1 Charlton MR, Kondo M, Roberts SK, Steers JL, Krom R, Wiesner R. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg 1997 ; 3: 359–364.
2. 2 Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001 ; 7: 797–801.
3. 3 Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study. Hepatology 2000 ; 32: 689–692.
4. 4 Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1999 ; 29: 664–669.
5. 5 Kingham JG. Dissecting out crytogenic liver disease. Gut 2000 ; 47: 328–329.
6. 6 Ku NO, Gish R, Wright TL, Omary B. Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med 2001 ; 344: 1580–1587.
7. 7 Ku NO, Wright TL, Terrault NA, Gish R, Omary B. Mutation of human keratin 18 in association with cryptogenic cirrhosis. J Clin Invest 1997 ; 99: 19–23.
8. 8 Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health and disease. Science 1998 ; 279: 514–519.
9. 9 Loranger A, Duclos S, Grenier A, Price J, Wilson‐Heiner M, Baribault H, Marceau N. Simple epithelium keratins are required for maintenance of hepatocyte integrity. Am J Pathol 1997 ; 151: 1673–1683.
10. 10 Omary MB, Ku NO, Toivola DM. Keratins: Guardians of the liver. Hepatology 2002 ; 35: 251–257.
11. 11 Gilbert S, Loranger A, Daigle N, Marceau N. Simple epithelium keratins 8 and 18 provide resistance to Fas‐mediated apoptosis. The protection occurs through a receptor‐targeting modulation. J Cell Biol 2001 ; 154: 763–773.
12. 12 Feng G, Kaplowitz N. Colchicine protects mice from the lethal effect of an agonistic anti‐ Fas antibody. J Clin Invest 2000 ; 105: 329–339.
13. 13 Ogasawara J, Watanabe‐Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti‐Fas antibody in mice. Nature 1993 ; 364: 806–809.
14. 14 Ni R, Tomita Y, Matsuda K, Ichihara A, Ishimura K, Ogasawara J, Nagata S. Fas‐mediated apoptosis in primary cultured mouse hepatocytes. Exp Cell Res 1994 ; 215: 332–337.
15. 15 Galle PR, Krammer PH. CD95‐induced apoptosis in human liver disease. Semin Liver Dis 1998 ; 18: 141–151.
16. 16 Faubion WA, Gores GJ. Death receptors in liver biology and pathobiology. Hepatology 1999 ; 29: 1–4.